AcrySof toric IOL offers spectacle independence

Article

The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon).

The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon), according to Paul Ernest from Jackson, USA.

Dr Ernest enrolled 480 patients and randomized them to receive either the control lens, AcrySof SA60AT single piece IOL (n=237), or the AcrySof toric IOL (n=243). Each patient had at least 0.75 D of regular astigmatism and age-related cataracts in one or both eyes.

The toric IOL patients reported a significantly greater rate of spectacle independence than controls (p<0.0001). Compared with controls, the percentage of toric patients achieving an uncorrected distance visual acuity (UDCVA) of 20/20 or better (19.4% versus 40.7%, respectively) or 20/25 or better (41.4% versus 63.7%, respectively) was significant (p<0.0001).

The comparison of the lenses demonstrates that the AcrySof toric IOL offers a much greater level of spectacle independence than its monofocal counterpart.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.